Skip to main content
OpenTrials
Completed

NCT Number: NCT02158442

Technology That Permits Focal Dose of Antibiotics to be Delivered to Lower Limb(s) of Diabetic Patients

The use of the Percutaneous Isolated Limb Procedure (PILP) which enables the use of existing antibiotic therapies in a more targeted and concentrated fashion in patients with diabetes who have a significant lower limb infection and it is deemed that IV antibiotics are needed in order to salvage the limb or life.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Royal Melbourne Hospital

Parkville, Victoria, 3050, Australia

About this study

During the PILP procedure, the circulation of the limb is isolated separately from the general circulatory system thereby enabling the delivery of antibiotics only to the limb. Limb isolation is achieved by creating an "artificial" circuit where catheters are inserted into the major artery and vein of the lower limb.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • M or F subjects 18 - 90 years old
  • Subject has pre-existing diabetes diagnosis
  • Subject has significant infection below the ankle of soft tissue and may include bone, and IV antibiotics are needed in order to salve limb or life
  • Consequence of infected wound would require Std of Care share debridement
  • Subject willing and able to provide written informed consent
  • Subject willing and able to comply with requirements of study protocol including pre-defined follow-up evaluations
  • PROCEDURAL INCLUSION CRITERIA: successful cannulation of the femoral artery and vein and placement of the venous support device

Exclusion criteria

  • Allergy to contrast media
  • Known bleeding disorder including thrombocytopenia
  • Recent AMI or elevated Troponin levels within last 30 days
  • Penicillin sensitivity; Timentin sensitivity
  • Female subjects known to be or suspected to be pregnant or lactating
  • Subject unable to comply with instructions; especially to remain supine for duration of recirculation procedure
  • Subjects who have participated in any other clinical trial or taken investigational drug within 30 days of study enrollment
  • The PI determines the subject is not an appropriate subject for the study
  • PROCEDURAL EXCLUSION CRITERIA: Subjects anatomy interferes with or is expected to prohibit successful cannulation of the femoral vessels or placement of the venous support device
  • Known severe proximal femoral artery vascular disease precluding placement of perfusion catheters

Treatment and study plan

Percutaneous Isolated Limb Perfusion (PILP) delivery

Procedure

The Percutaneous Isolated Limb Perfusion (PILP) delivery intervention procedure enables the use of existing antibiotic therapies in a more targeted and aggressive fashion; it addresses limitations associated with the use of conventional antibiotic drug delivery. As part of the procedure, the circulation of the limb is isolated separately from the general circulatory system enabling the delivery of antibiotic at high therapeutic doses that are not achievable when standard doses are administered intravenously.

Timentin

Drug

The Control Group will receive standard dosings of intravenous Timentin plus other standard care.

Other names: Ticarcillin and Clavulanate

Primary outcomes

  1. Efficacy of Timentin Delivered by PILP Procedure (Treatment Group) Versus Intravenous Delivery (Control Group) at Reducing Microbiological Load in Subjects With Diabetes, and Significant Wound Infection of the Lower Limb.

    Time frame: Day 3

    Reduction in microbiological load, including assessment of CFU, infection type and antibiotic sensitivity between the two groups over time. To compare the efficacy of Timentin delivered by PILP procedure (Treatment Group) versus intravenous delivery (Control Group) at reducing microbiological load in subjects with diabetes, and significant wound infection of the lower limb.

Sponsors and collaborators

Lead sponsor

Osprey Medical, Inc

Industry

Registry information

Official study title

Randomized Study Comparing Clinical and Microbiological Efficacy of Timentin Delivered Via Percutaneous Isolated Limb Perfusion (PILP) or Intravenous Infusion in Diabetic Subjects With Moderate to Severe Lower Limb Infection

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Jun 6, 2014
Registry last updated
Sep 30, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.